Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 0.62 |
| ▸ | PTGDR | Q13258 | 8/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17907964 | 0.90 | PTGDR2 (0.56) | PTGDR2PTGDRTBXA2R | |
| SCHEMBL13279672 | 0.90 | PTGDR2 (0.58) | PTGDR2PTGDRTBXA2R | |
| SCHEMBL17907925 | 0.90 | PTGDR2 (0.58) | PTGDR2PTGDRTBXA2RCYP3A4CYP2C9 | |
| SCHEMBL17907940 | 0.89 | PTGDR2 (0.59) | PTGDR2PTGDRTBXA2R | |
| SCHEMBL17907943 | 0.89 | PTGDR2 (0.59) | PTGDR2PTGDRTBXA2RCYP3A4CYP2C9 | |
| SCHEMBL17907959 | 0.89 | PTGDR2 (0.56) | PTGDR2PTGDRTBXA2R | |
| SCHEMBL17908003 | 0.85 | PTGDR2 (0.61) | PTGDR2PTGDRTBXA2R | |
| SCHEMBL13281979 | 0.85 | PTGDR2 (0.54) | PTGDR2PTGDRTBXA2RCYP2C9 | |
| SCHEMBL17908004 | 0.82 | PTGDR2 (0.50) | PTGDR2PTGDR | |
| SCHEMBL13278870 | 0.80 | PTGDR2 (0.52) | PTGDR2PTGDRTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2697223-B1 | 7-(HETEROARYL-AMINO)-6,7,8,9-TETRAHYDROPYRIDO[1,2-A]INDOL ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-07-13 | — | — | EP | disclosed |